1. Signaling Pathways
  2. Immunology/Inflammation
  3. Interleukin Related
  4. Interleukin Related Inhibitor

Interleukin Related Inhibitor

Interleukin Related Inhibitors (1358):

Cat. No. Product Name Effect Purity
  • HY-176274
    FASN/SCD-IN-1
    Inhibitor
    FASN/SCD-IN-1 is a Silybin (HY-N0779A) derivative, an orally active inhibitor of Fatty Acid Synthase (FASN)/Stearoyl-CoA Desaturase (SCD). FASN/SCD-IN-1 has shown in vitro activity in inhibiting lipid deposition, reducing FASN and SCD transcriptional levels, and exhibiting antioxidant, anti-inflammatory, and anti-fibrotic activities. FASN/SCD-IN-1 has demonstrated significant hepatoprotective effects in a rat model of acute liver injury. FASN/SCD-IN-1 ameliorates the pathological features of MASH liver, including steatosis, inflammation, and fibrosis in a mouse model of myeloproliferative steatohepatitis (MASH). FASN/SCD-IN-1 can be used to study MASH.
  • HY-167845
    LD03-DEX
    Inhibitor
    LD03-DEX is a precursor compound of dexamethasone (HY-14648) with immunosuppressive activity.
  • HY-14575
    Nastorazepide hemicalcium
    Inhibitor
    Nastorazepide (Z-360) hemicalcium is an orally active 1,5-benzodiazepine derivative and gastrin/CCK-2 receptor antagonist. Nastorazepide hemicalcium inhibits the specific binding of [3H]CCK-8 to the human CCK-2 receptor with a Ki value of 0.47 nM. Nastorazepide hemicalcium inhibits IL-1β, ephrin B1, VEGF, and HIF-1alpha, reduces Akt and NR2B phosphorylation. Nastorazepide hemicalcium has antitumor activity against pancreatic cancer. Nastorazepide hemicalcium inhibits colorectal cancer liver metastasis and relieves pain.
  • HY-180155
    Keap1/Nrf2/ARE activator 2
    Inhibitor
    Keap1/Nrf2/ARE activator 2 is an activator of Keap1/Nrf2/ARE pathway and non-competitively inhibits AChE with an IC50 of 14.79 μM and a Ki of 1.35 μM. Keap1/Nrf2/ARE activator 2 promotes Nrf2 nuclear translocation, leading to antioxidant gene upregulation and enhanced cellular defense against oxidative stress. Keap1/Nrf2/ARE activator exhibits robust neuroprotection against both H2O2- and Scopolamine (SCA) (HY-N0296)-induced injury in PC12 cells. Keap1/Nrf2/ARE activator 2 ameliorates memory impairment and the neuro-inflammation associated with SCA-initiated cognitive dysfunction in a zebrafish model. Keap1/Nrf2/ARE activator 2 can be used for the research of Alzheimer's disease.
  • HY-153330
    TNF-α-IN-10
    Inhibitor
    TNF-α-IN-10 (compound 8a) is a IL-6 and TNF-α inhibitor. TNF-α-IN-10 shows anti-inflammatory activity.
  • HY-181827
    IL-17-IN-7
    Inhibitor
    IL-17-IN-7 (Compound 23) is a IL-17 inhibitor with a pIC50 of 7.1 against IL-17A.
  • HY-126042R
    (±)-Lisofylline (Standard)
    Inhibitor
    (±)-Lisofylline (Standard) is the analytical standard of (±)-Lisofylline. This product is intended for research and analytical applications. (±)-Lisofylline ((±)-Lisophylline) is the racemate of Lisofylline. Lisofylline inhibits the generation of phosphatidic acid and free fatty acids. Lisofylline also blocks the release of pro-inflammatory cytokines in oxidative tissue injury, in response to cancer chemotherapy and in experimental sepsis. Lisofylline can be used for Type 1 diabetes research.
  • HY-181818
    4,5-Dehydro-6-oxoallosecurinine
    Inhibitor
    4,5-Dehydro-6-oxoallosecurinine is a Keap1-Nrf2 pathway activator. 4,5-Dehydro-6-oxoallosecurinine promotes the nuclear translocation of Keap1-Nrf2, and induces the expression of antioxidant and cytoprotective genes. 4,5-Dehydro-6-oxoallosecurinine reduces the production of NO, and decreases the levels of iNOS, TNF-α, IL-6 and IL-1β in LPS-stimulated microglia. 4,5-Dehydro-6-oxoallosecurinine can be used for the research of neurodegenerative diseases.
  • HY-B0513R
    Methylthiouracil (Standard)
    Inhibitor
    Methylthiouracil (Standard) is the analytical standard of Methylthiouracil. This product is intended for research and analytical applications. Methylthiouracil is an antithyroid agent. Methylthiouracil suppresses the production TNF-α and IL-6, and the activation of NF-κB and ERK1/2.
  • HY-107352R
    Fosfenopril (Standard)
    Inhibitor
    Fosfenopril (Standard) is the analytical standard of Fosfenopril. This product is intended for research and analytical applications. Fosfenopril (Fosinoprilat) is a potent angiotensin converting enzyme (ACE) inhibitor. Fosfenopril alleviates lipopolysaccharide (LPS)-induced inflammation by inhibiting TLR4/NF-κB signaling in monocytes.
  • HY-N12042
    Taxamairin B
    Inhibitor
    Taxamairin B is a potent anti-inflammatory agent. Taxamairin B decreases proinflammatory cytokines (TNF-α, IL-1β and IL-6) expression and the production of NO and ROS in LPS-induced RAW264.7 cells. Taxamairin B exhibits significant protective effects in LPS-induced acute lung injury in mice.
  • HY-178447
    PPARγ agonist 20
    Inhibitor
    PPARγ agonist 20 is a potent, orally active PPAR-γ agonist. PPARγ agonist 20 effectively increases antioxidant defenses (SOD, GSH) and reduces lipid peroxidation. PPARγ agonist 20 can upregulate of Pparg, Glut4, and AdipoQ, suppresses of TNF-α, IL-6, and NF-κB p65. PPARγ agonist 20 significantly lowers fasting blood glucose, improving glucose tolerance, and restoring metabolic balance in Streptozotocin (HY-13753)-Nicotinamide (HY-B0150)-induced diabetic rats. PPARγ agonist 20 can be used for the study of type 2 diabetes.
  • HY-RS06671
    Il10 Mouse Pre-designed siRNA Set A
    Inhibitor

    Il10 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Il10 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

  • HY-N8593S
    Undecane-d24
    Inhibitor
    Undecane-d24 is the deuterium labeled Undecane (HY-N8593).Undecane is a potent cAMP agonist with anti-allergic and anti-inflammatory activities. Undecane inhibits degranulation and the secretion of histamine and TNF-α. Undecane reverses the increased levels of p38 phosphorylation, NF-κB transcriptional activity and target cytokine/chemokine genes, including thymus and activation-regulated chemokine (TARC), macrophage-derived chemokine (MDC) and interleukin-8 (IL-8). Undecane can be used for the study of skin inflammatory disorders, such as atopic dermatitis.
  • HY-178465
    EP4 receptor antagonist 8
    Inhibitor
    EP4 receptor antagonist 8 is an orally active EP4 antagonist (human EP4 IC50 = 6.40 nM). EP4 receptor antagonist 8 significantly reduced paw and joint swelling, inflammatory cell infiltration, cartilage damage, pannus formation, and joint bone erosion in arthritis (AIA) mice in a dose-dependent manner. EP4 receptor antagonist 8 can be used for the study of inflammatory pain.
  • HY-P991256
    FB-825
    Inhibitor
    FB-825 is a human monoclonal antibody (mAb) targeting IGHE. FB-825 targets the CεmX domain of membrane IgE (mIgE), resulting in the downregulation of mIgE-positive B cells and the production of IgE. FB-825 can be used in Allergic asthma, Atopic dermatitis, Job syndrome and Allergic rhinitis research.
  • HY-P991091
    COVA322
    Inhibitor
    COVA322 is a bispecific TNF and IL-17A antibody. COVA322 inhibits simultaneously TNF and the IL-17A homodimer that can be used for the study of inflammatory diseases.
  • HY-N17850
    5-Hydroxy-6,7-dimethoxyflavone
    Inhibitor
    5-Hydroxy-6,7-dimethoxyflavone is an orally active inhibitor of ferroptosis (Ferroptosis). 5-Hydroxy-6,7-dimethoxyflavone inhibits H1N1 virus-induced ferroptosis by upregulating the expression of SLC7A11 and GPX4. 5-Hydroxy-6,7-dimethoxyflavone alleviates inflammatory responses and inhibits apoptosis by suppressing the activation of the NF-κB and p38 MAPK signaling pathways. 5-Hydroxy-6,7-dimethoxyflavone can be used in studies related to H1N1 influenza virus infection.
  • HY-181926
    COX-2/HDAC6-IN-1
    Inhibitor
    COX-2/HDAC6-IN-1 (Compound 11e) is a dual COX-2 and HDAC6 inhibitor, with an IC50 of 0.12 μM against HDAC6 and an IC50 of 0.66 μM against COX-2. COX-2/HDAC6-IN-1 enhances the acetylation level of α-tubulin, regulates epigenetic gene expression, and inhibits the expression of pro-inflammatory mediators (COX-2, IL-1β, IL-6 and TNF-α). COX-2/HDAC6-IN-1 promotes Amyloid-β clearance and reduces excessive phosphorylation of Tau protein. COX-2/HDAC6-IN-1 maintains neuronal morphology by stabilizing MAP2, protects synaptic integrity by regulating synapsin, and restores the expression of memory-related genes. COX-2/HDAC6-IN-1 possesses neuroprotective activity and improves learning and memory abilities in Scopolamine (HY-N0296)-induced Alzheimer's disease mouse models. COX-2/HDAC6-IN-1 is applicable to research related to Alzheimer's disease.
  • HY-P992022
    AK114
    Inhibitor
    AK114 is an anti-human interleukin-1 beta (IL-1β) imonoclonal antibody. AK114 binds to interleukin-1 beta and prevents its binding to the IL-1 receptor, suppresses inflammatory responses, tumorigenesis, and angiogenesis mediated by interleukin-1 beta.AK114 exhibits anti-inflammatory, immunomodulating, and antineoplastic activities.